4.15
0.04 (0.97%)
| Penutupan Terdahulu | 4.11 |
| Jumlah Dagangan | 23,543 |
| Harga / Jualan (P/S) | 2.55 |
| Harga / Buku (P/B) | 18.63 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -236.41% |
| EPS Cair (TTM) | -11.40 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -10.10% |
| Nisbah Semasa (MRQ) | 1.34 |
| Aliran Tunai Operasi (OCF TTM) | -53.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -32.56 M |
| Pulangan Atas Aset (ROA TTM) | -62.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,546.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Verrica Pharmaceuticals Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.93 |
|
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 44.90% |
| % Dimiliki oleh Institusi | 32.25% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |